Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
The literature on this class of medications primarily highlights that they are generally well-tolerated with a low incidence of significant neurological adverse events
Shirai, M., Hiramatsu, I., Aoki, Y., Shimoyama, H., Mizuno, T., Nozaki, T., Fukuhara, S., Iwasa, A., Kageyama, S., & Tsujimura, A
HSA and FSA accounts also qualify, making precision semaglutide therapy accessible to more patients seeking personalized weight loss support
Can J Diabetes 2022 46:449-56
A comprehensive review of clinical trials from 2021 highlights that once-weekly subcutaneous semaglutide (1 mg) consistently lowered HbAc by 1.5 to 1.8% over 30 to 56 weeks, outperforming other medications including sitagliptin, dulaglutide, and insulin glargine in the SUSTAIN series.33 Real-world data from 2023 further support these findings, showing an average HbA1c reduction of approximately 0.9% and a fasting blood glucose decrease of 26 mg/dL after six months of once-weekly semaglutide use.34 These results underscore semaglutides ability to offer meaningful improvements in glycemic control and metabolic health for patients with T2DM
